Jennifer Conner, PA
Medical · Indianapolis, INNPI 1669540969
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,094 of the $98,112 with a category attached, or 66.3%. 32 manufacturers reported payments, led by Arcutis Biotherapeutics, Inc. at 48.6% of the total. 2025 is the largest year on record at $33,981, 5.6 times the $6,070 reported in 2021. Among medical clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 881 payments — averaging $111.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$48K
- Novartis$20K
- AbbVie$6K
- Kowa Pharmaceuticals America, Inc.$4K
- Incyte Corporation$4K
- UCB, Inc.$2K
- plus $15K from 26 others
What the payments were for
- Consulting fees$65,09466%
- Speaking & faculty fees$8,6949%
- Travel & lodging$7,1247%
- Food & beverage$16,67517%
- Education$5251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 79 | $47,728 |
| Novartis | 209 | $19,507 |
| AbbVie | 109 | $5,511 |
| Kowa Pharmaceuticals America, Inc. | 4 | $4,158 |
| Incyte Corporation | 50 | $4,156 |
| UCB, Inc. | 37 | $2,161 |
| Dermavant Sciences, Inc. | 29 | $1,858 |
| Journey Medical Corporation | 7 | $1,758 |
| LEO Pharma Inc. | 12 | $1,588 |
| Boehringer Ingelheim | 13 | $1,459 |
| Pfizer | 67 | $1,435 |
| E.r. Squibb & Sons, L.L.C. | 36 | $1,228 |
| Amgen | 37 | $887 |
| Johnson & Johnson | 39 | $816 |
| Regeneron Healthcare Solutions, Inc. | 26 | $772 |
| Lilly USA, LLC | 47 | $771 |
| Sun Pharmaceutical Industries Inc. | 20 | $682 |
| Galderma Laboratories, L.p. | 27 | $419 |
| Almirall LLC | 2 | $406 |
| Sanofi | 6 | $172 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $159 |
| Stemline Therapeutics Inc. | 1 | $112 |
| Organon | 5 | $85 |
| Sanofi-aventis U.S. LLC | 2 | $58 |
| Bausch Health US, LLC | 1 | $45 |
| VYNE Pharmaceuticals Inc. | 2 | $41 |
| Mayne Pharma Commercial LLC | 4 | $40 |
| Fresenius Kabi USA, LLC | 2 | $38 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
| Mylan Institutional Inc. | 1 | $16 |
| Botanix SB Inc | 1 | $16 |
| EPI Health, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,112 in reported general payments places this provider in the 95th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 49 | $238,362 |
| Humira(Cf) PenAdalimumab | 13 | $176,484 |
| Cosentyx Unoready PenSecukinumab | 12 | $110,023 |
| Dupixent PenDupilumab | 17 | $62,515 |
| Clobetasol Propionate | 102 | $5,028 |
| Fluorouracil | 33 | $2,301 |
| Ketoconazole | 141 | $2,075 |
| Tacrolimus | 12 | $1,867 |
| Clindamycin Phosphate | 39 | $1,459 |
| Fluocinonide | 33 | $1,440 |
| Metronidazole | 36 | $1,191 |
| Triamcinolone Acetonide | 90 | $1,069 |
| Doxycycline Hyclate | 63 | $807 |
| Hydroxychloroquine Sulfate | 14 | $643 |
| Minocycline Hcl | 31 | $624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $887 | $238,36249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 273 medical providers in Indiana.
Other medical in Indianapolis
- Meggie BeckleyIndianapolis$125K
- Jennifer IrwinIndianapolis$34K
- Andrew BurnsIndianapolis$13K
- Bridget WilliamsonIndianapolis$11K
- Lindsay MuellerIndianapolis$9K
- Meredith SlayterIndianapolis$8K
- Chelsea WilsonIndianapolis$5K
- Rachel SandersonIndianapolis$4K
- Ryan StromIndianapolis$4K
- Amanda EckhardtIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.